| 1 |
33565361 | MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis. | 2022 Jan |
1 |
| 2 |
34963561 | CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. | 2022 Jan 15 |
1 |
| 3 |
35129779 | Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. | 2022 Apr |
1 |
| 4 |
33129240 | Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response. | 2021 Jan |
1 |
| 5 |
33607534 | Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells. | 2021 Mar |
2 |
| 6 |
33707832 | Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study. | 2021 Jan |
1 |
| 7 |
33995081 | ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans. | 2021 |
3 |
| 8 |
34144313 | Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line. | 2021 Oct |
2 |
| 9 |
34410954 | Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model. | 2021 Sep-Oct |
3 |
| 10 |
32112424 | The potentiation of menadione on imatinib by downregulation of ABCB1 expression. | 2020 Jun |
1 |
| 11 |
32415468 | Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects. | 2020 Jul |
2 |
| 12 |
32715517 | Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients. | 2020 Sep |
3 |
| 13 |
33086089 | Downregulation of MDR 1 gene contributes to tyrosine kinase inhibitor induce apoptosis and reduction in tumor metastasis: A gravity to space investigation. | 2020 Dec 15 |
1 |
| 14 |
33244077 | Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients. | 2020 Nov 26 |
2 |
| 15 |
30956965 | ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy. | 2019 Mar |
3 |
| 16 |
31262905 | Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. | 2019 Jul |
1 |
| 17 |
31759356 | Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients. | 2019 Nov 1 |
3 |
| 18 |
28762371 | Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. | 2018 May 22 |
3 |
| 19 |
29808796 | Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms. | 2018 May 15 |
1 |
| 20 |
29945498 | Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia. | 2018 Dec |
1 |
| 21 |
30186389 | Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression. | 2018 Sep |
4 |
| 22 |
33177018 | [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia]. | 2018 Jan 30 |
3 |
| 23 |
27416909 | The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. | 2017 Jan |
3 |
| 24 |
27875938 | The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. | 2017 May |
3 |
| 25 |
28190319 | LncRNA MEG3 Regulates Imatinib Resistance in Chronic Myeloid Leukemia via Suppressing MicroRNA-21. | 2017 Sep 1 |
1 |
| 26 |
28289867 | Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. | 2017 Apr |
2 |
| 27 |
28330783 | Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. | 2017 Jun |
6 |
| 28 |
28367681 | Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? | 2017 Sep |
1 |
| 29 |
28623111 | Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. | 2017 Aug 1 |
4 |
| 30 |
28836054 | Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia. | 2017 Oct |
5 |
| 31 |
26250462 | Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. | 2016 Jan |
1 |
| 32 |
27050374 | Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells. | 2016 May 3 |
2 |
| 33 |
27168851 | Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia. | 2016 May |
3 |
| 34 |
27268766 | ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. | 2016 Jun |
4 |
| 35 |
27405085 | Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. | 2016 Jul 12 |
7 |
| 36 |
27418107 | TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux. | 2016 Oct |
1 |
| 37 |
27536777 | ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. | 2016 |
1 |
| 38 |
27770655 | Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice. | 2016 Dec |
2 |
| 39 |
25245580 | ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. | 2015 Apr |
1 |
| 40 |
25482933 | Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. | 2015 |
1 |
| 41 |
25908454 | Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines. | 2015 May |
1 |
| 42 |
25916699 | Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways. | 2015 Jul |
3 |
| 43 |
26546461 | A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients. | 2015 Dec |
2 |
| 44 |
26634458 | Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia. | 2015 Nov 24 |
1 |
| 45 |
27294449 | C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia. | 2015 Nov-Dec |
3 |
| 46 |
23683876 | Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. | 2014 Apr |
2 |
| 47 |
24088895 | Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib. | 2014 Jan 1 |
2 |
| 48 |
24107928 | Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. | 2014 Mar |
2 |
| 49 |
24472814 | MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. | 2014 Jul |
4 |
| 50 |
24581936 | Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. | 2014 Apr |
1 |